Recombinatory Hemagglutinin In Mammalian Cells For Vaccine Production | 11207
Journal of Clinical & Cellular Immunology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Influenza hemagglutinin (HA) is an antigenic glycoprotein presented on the surface of virus and plays critical roles for the
entry of virus into the cell. It has been implied as a primary target to produce neutralizing antibodies to prevent the viral
infection. Although approved by US Food and Drug Administration, the current production process for the three vaccines takes
about 6 months and their antigenic compositions must be modified annually. Therefore, multiple attempts have been described
to develop novel methods to replace the traditional vaccine production technology. One of the studies that has been proved as
safe and efficient on clinical trials is to directly inject recombinatory HA (rHA) into human subjects to produce neutralizing
antibodies. However, the rHA used in those studies were purified from insect expression systems rather than mammalian cells.
Here, we used different expression vectors trying to over express rHA in mammalian cells. Both western blots and fluorescence
imaging data suggested only very few amounts of rHA expressed in cells by common vectors pcDNA3.1 and gateway destination
vector pDEST40. However, rHA can be greatly over expressed in mammalian cells when
was constructed into lentiviral
vector. Endo H assay and sucrose density gradient fractionation experiment confirmed rHA was folded and trafficked correctly
in the cell. Furthermore, hemadsorption assay verified the functionality of rHA. In summary, we built a stable mammalian cell
line to successfully over express rHA that could be useful to produce influenza vaccine.
Jiansong Tong completed his Ph.D. from Department of Biochemistry, Biophysics and Molecular Biology at Iowa State University at Ames, Iowa USA.
Currently, he is a research associate in Department of Cell Biology at The Scripps Research Institute at La Jolla, CA USA. He has published several
papers in esteemed journals including
PNAS, Nucleic Acids Res, JBC
BMC Systems Biol
etc. He has also served as an editorial board member
Journal of Clinical and Cellular Immunology
since year 2010 and associate editor for
Journal BMC Biotechnology
from year 2013.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals